2018 Agenda                   

Washington, DC, 25 - 26 October 2018

Schedule

Create your personal agenda –check the favourite icon

Oct 2508:50
Conference pass

Chairperson's Opening Remarks

Keynotes
Kevin Outterson, Executive Director, CARB-X
Oct 2508:55
Conference pass

Keynote address: Leading the industry in novel class antibiotics and stewardship initiatives – coordinated efforts in stewardship, diagnostics and drug development to fight resistance

Keynotes
  • Moving past commercial stage to conduct AMR surveillance through post marketing susceptibility testing and real-world evidence use registries
  • Economics of stewardship – evaluating economic models to support the responsible and sustainable use of antibiotics
  • Ensuring appropriate antibiotic use through coordinated educational efforts with providers
  • What next? How CARB-X funding is impacting Melinta’s pipeline of novel class antibiotics to further combat resistance
Oct 2509:20
Conference pass

Keynote address: Coordinated Pull – engaging all stakeholders to make “pull” incentives a reality

Keynotes
  • How can industry, regulators and funders come together to implement effective pull incentives
  • Using evidence provided buy studies like the DRIVE AB report to influence policy makers
  • Looking at different funding models with continuous clinical evaluation
  • Picking the baton from push initiatives to achieve viable commercial feasibility
  • Analyzing market entry rewards, transferable vouchers, and FDA proposed licensing model
Moderator: Greg Frank, Director, Infectious Disease Policy, BIO
Mark Jones, Head of Clinical Development and Preclinical Development, Basilea Pharmaceutica Ltd
Amanda Jezek, Senior VP, Public Policy and Government Relations, Infectious Diseases Society of America
Jeremy Knox, Policy and Advocacy Lead, Drug-Resistant Infections Programme, Wellcome Trust
Oct 2510:05
Conference pass

Keynote address – Sponsored Session

Keynotes
If you’re interested in sponsoring this session contact Fred Sansiveri at fred.sansiveri@terrapinn.com or +1 646 619 1838
Oct 2511:30
Conference pass

LPAD – new pathways for antibacterial drug development

Antibiotic R&D
  • Creating pathways for companies to reinvigorate antibacterial R&D with limited number of patients in clinical trails
  • Reestablishing a balance in FDA’s antibacterial risk-benefit decision making
  • Review - how is it working and what is the future of this clinical trial pathway
Dmitri Iarikov, Deputy Director in the Division of Anti-Infective Products, FDA
Oct 2511:30
Conference pass

Gaps in diagnostics innovation and areas for further technological development

Diagnostics
  • What are the next steps for diagnostic developers to meet the demand for innovation based on the WHO’s Essentials Diagnostics list
  • Uncovering the barriers and opportunities in developing diagnostics for low resource settings
Rangarajan Sampath, Chief Scientific Officer, FIND
Oct 2511:30
Conference pass

How Aetna leverages federal, state, and private sector collaborations to promote antibiotic stewardship

Antimicrobial Stewardship
  • Implementing data driven approaches to encourage behavior change among providers and consumers
  • Aetna, CDC, and State DOHs ‘nudging’ providers to promote evidence-based treatment practices for acute infections
  • Fostering innovative partnerships to reduce the incidence of hospital acquired infections and inappropriate prescribing
Oct 2511:30
Conference pass

VC Panel: Funding for innovative traditional drugs as well as non-traditional antibiotic development

Innovation Showcase
  • Investing in traditional innovation in the antibiotic space
  • Non-traditional products and pipeline a private funders perspective.
  • What is the future of additional VC funding for both traditional and non-traditional antibiotics and innovation
Moderator: Nicole Mahoney, Director, Global Regulatory Policy, Merck
Henry Skinner, Senior Vice President, Tekla Capital Management
Steve Nagler, Executive Director, MedPro Investors LLC
Oct 2511:55
Conference pass

CARB-X Turns 2!

Antibiotic R&D
  • Is the X model working?
  • What have we learned about accelerating global antibacterial innovation
  • Our vision of expanding this global antibacterial innovation fund
  • What’s next for CARB-X and for BARDA
Oct 2511:55
Conference pass

New technologies: Full pipeline overview of new rapid and susceptibility testing technologies

Diagnostics
  • What are the technologies that are close to market for susceptibility testing and rapid DX and will they close the gap for industry?
  • How will regulation influence the potential and timeline of the diagnostic pipeline
  • What are the differing opinions of the effectiveness of these technologies
Oct 2511:55
Conference pass

Putting Vision into Practice: Innovative IT Strategies to Improve Antibiotic Prescribing

Antimicrobial Stewardship
  • Developing and deploying a global, mobile-based software solution for antimicrobial stewardship and infection control in Latin America
  • Creating a regional surveillance platform for coordinated tracking, alerting and management of multi-drug resistant pathogens
  • Employing predictive analytics to personalize traditional antibiograms
Brandon Palermo, CMO at ILUM Health Solutions and Executive Director and CMO, Merck & Co
Oct 2512:15
Conference pass

Antibiotic Development – Successes, incentives and unintended consequences

Antibiotic R&D
  • Examining the impotence of push and pull incentives
  • What makes for success for recent approvals
  • What to expect in the next 5 years
Oct 2512:15
Conference pass

After push funding: innovation in rapid diagnostics, powered by CARB-X funding

Diagnostics
  • Sparking innovation in translational science and diagnostic development to shorten time to diagnosis for bacterial respiratory infections
  • Initiating conversations with funders in early stage diagnostic development
  • Milestones for diagnostic development in CARB-X nondilutive funding
  • Preparations for commercialization and additional rounds of VC funding pull funding or reimbursement
Kev Dhaliwal, Team Leader, EPSRC Proteus IRC
Oct 2512:15
Conference pass

The Melinta Antimicrobial Stewardship Program: A New Effort to Address a Public Health Priority

Antimicrobial Stewardship
  • Implementing stewardship measures within Melinta’s R&D, manufacturing, soligenand commercial operations
  • Executing AMR surveillance including post-marketing susceptibility testing and real-world use registries
  • Supporting responsible and sustainable use of Melinta products through educating healthcare providers and evaluating economic models
Oct 2512:15
Conference pass

Stimulating R&D for new Antimicrobials to address global public needs in AMR

Innovation Showcase
  • Need for multi-actors interventions to refill the pipeline
  • Role and objectives of a PPP in the space along with other initiatives.
  • Global and regional impact of drug-resistant infections
Jean-Pierre Paccaud, Director, Business Development and Corporate Strategy, Global Antibiotic Research and Development Partnership (GARDP)
Oct 2512:35
Conference pass

Stealth targeted nanoparticles (STN): A platform to fast-track poorly bioavailable antibiotics into Oral dosage form

Antibiotic R&D
  • Conundrums of IV to Oral shift: Clinical implications
  • Our experiences from the STN Development Programme
  • Advancing IV breakthrough drugs to Oral therapy during drug development programs
  • Redefining the economics of antibiotic drug development
Oct 2512:35
Conference pass

Advancing biofilmograms to better detection and treatment of Diabetic Foot Ulcer (DFU)

Diagnostics
  • Characteristics of the Diabetic Foot Ulcer (DFU) as a recurring complication of diabetes and the requirement of long-term treatment
  • Societal burden and the high cost that DFU represents in healthcare systems of high-income countries (4 billion € yearly)
  • Importance of bacterial interactions on the skin surface in the pathophysiology of DFU and time to healing
  • Challenges of effectively diagnosing presence and role of biofilm in these infections and choosing the right treatment
Enea Di Domenico, Clinical Pathology and Microbiology, Istituti Fisioterapici Ospitalieri
Oct 2512:35
Conference pass

Preventing Hospital Acquired Infections – review of clinical trials for Ribaxamase in the prevention of Clostridium difficile Infections

Antimicrobial Stewardship
  • New product compound in development being designedto prevent deleterious effects of certain IV beta-lactam antibiotics, through gut microbiome protection
  • Potential to support successful antimicrobial stewardship programs (ASPs) by reducing Hospital Acquired Infections and potentially reducing Antimicrobial Resistance (AMR)
  • Why Ribaxamase has the potential to provide an additional strategic options for Infection Preventionist and Infection Control Specialists
Oct 2512:35
Conference pass

Update from CARB-X

Innovation Showcase
  • Main areas of focus – who and what CARB-X funds
  • Understanding CARB-X’s the global reach, application process and decision making process
  • Looking into what stage of development is funded
Oct 2513:25
Conference pass

Lunch Keynote: The Other Pipeline Problem - Where are the AMR Experts?

Keynotes
Paul Auwaerter, President, Infectious Diseases Society of America IDSA
Oct 2514:30
Conference pass

Roundtable 1: Fighting Infections – AntiMicrobial non-antibiotic strategies to address specific chronic infections

Keynotes
Yannick Pletan, Acting Chief Medical Officer, Biofilm Pharma
Jean-Philippe Lavigne, Clinical Microbiologist, Centre Hospitalier Régional Universitaire De Nimes
Oct 2514:30
Conference pass

Roundtable 2: Hostcentricity - a discussion on the undeniable superorganisms of human and animal health, and their contribution to holistic and sustainable antimicrobial stewardship

Keynotes
Brian Michael Aldridge, Clinical Professor, Department of Veterinary Clinical Medicine, University of Illinois College of Veterinary Medicine
Oct 2514:30
Conference pass

Roundtable 3: Hematology/Oncology ASP – a successful reduction of antimicrobial usage in high risk hematology/ BMT/ oncology patients

Keynotes
Sanjeet Dadwal, Associate Clinical Professor Head of Antimicrobial Stewardship Program, City of Hope
Oct 2514:30
Conference pass

Roundtable 4: Industry & Agriculture – what strategies may both benefit the industry and also the consumer as well as preventing increased AMR as a result of unregulated use in agriculture

Keynotes
Oct 2514:30
Conference pass

Roundtable 5: Supporting Development – BARDA’s role in stimulating innovation in preclinical antibacterial research and development, and addressing key issues of resistance

Keynotes
Oct 2514:30
Conference pass

Roundtable 6: Restoration Therapy – Microbiata-based drug candidates promise to change drug resistance characteristics of the microbiome

Keynotes
Lee Jones, Founder, President and Chief Executive Officer, Rebiotix, Inc.
Oct 2514:30
Conference pass

Roundtable 7: Sustainable incentives – pharmaceutical perspective on immediate actions and long-term solutions

Keynotes
Keiko Tone, VP Market Access, Shionogi Limited
Oct 2514:30
Conference pass

Roundtable 8: Catch 22 - Antimicrobial stewardship: reports, penalties, and payers, oh my!

Keynotes
Oct 2514:30
Conference pass

Roundtable 9: "Trial awareness– connecting Industry, clinicians and patients to advance C. diff. clinical trials.”

Keynotes
Nick Van Hise, Infectious Diseases Clinical Pharmacy Specialist, Research Coordinator, Metro Infectious Disease Consultants
Nancy Caralla, Founding President and Executive Director, C Diff Foundation
Oct 2514:30
Conference pass

The functions, failures, successes and future of Efflux Pump Inhibitors

Innovation Showcase
  • Understanding the role of efflux in antibiotic resistance and why previous attempts to develop EPI’s have failed
  • Solving toxicity issues through TAXIS-designed structures to resurrect myriad antibiotics targeting multiple ESKAPE pathogens
  • Commercialization of EPI’s: from low-cost generics to lifecycle brand management
Oct 2514:50
Conference pass

Developing sequence engineered peptide antibiotics as a new drug class to address MDR bacterial infections

Innovation Showcase
  • Proprietary sequence engineering platform allows creation of differentiated peptide antibiotic pipeline
  • Unique activity and safety profile allows for development toward local and systemically-administered indications
  • Lead products advancing into clinic in H2 2018
Oct 2515:10
Conference pass

Precision medicine in infectious disease

Innovation Showcase
A rapid, flexible & low-cost genomics-based AMR platform to enable infections to be treated with simpler, safer and cheaper antibiotics and slow the development of resistance
Oct 2515:30
Conference pass

NIH programs to combat antimicrobial resistance

Antibiotic R&D
  • NIH basic science: enabling innovative product development to combat AR
  • NIH support for traditional and non-traditional therapeutics to combat AR
  • NIH funding opportunities to combat AR
Oct 2515:30
Conference pass

Hospitals as customers: understanding how hospitals are buying diagnostics in the current market

Diagnostics
  • What should hospital CEOs consider when buying diagnostic products
  • What is the role of antibiotic stewardship programs and RDT
  • What do diagnostic companies need to do differently to increase hospital purchasing
Oct 2515:30
Conference pass

The implications of antimicrobial resistance at the clinic and the bedside

Antimicrobial Stewardship
  • History of resistance with patient perspectives
  • What we have been able to accomplish through stewardship and increased support for drug development of new antimicrobials
  • What resources are needed to further decrease the development of resistance and spread of current MDROs
Oct 2515:30
Conference pass

New antimicrobial strategy and new innovative pure antibiofilm treatments

Innovation Showcase
  • The biofilm paradigm - at the edge of new diagnostic and therapeutic strategies
  • New antimicrobials with antibiofilm profiles and targeted clinical applications
  • Rational purpose - treatment vs prevention
  • New drugs strategies, new financing opportunities and the European experience
Olivier Favre Bulle, Founder and Consultant in Drug Development and Business Strategy, 3Biotech
Marie Petit, Coordinator, The Beam Alliance
Oct 2515:50
Conference pass

The UK’s response to the development of new therapeutics to tackle critical drug resistant infections

Antibiotic R&D
    li>
  • Presenting an overview of the AMR therapeutics landscape in the UK from an industrial perspective
  • Particularly describing the key role that small-to-medium enterprises (SMEs) are playing, and the AMR Centre’s role in accelerating programs into clinical trials
  • Highlighting the importance of international collaboration and funding for the successful development of new drugs against AMR
Oct 2515:50
Conference pass

Phases in Evaluations of Diagnostics & Implications for Clinical Stances

Diagnostics
  • What are the key steps and considerations in the assessment of diagnostics?
  • Present & discuss the assessment processes using standard parameters & guides
  • Proposals for understanding and overcoming the lack of support through robust evidence
Eugean Jiwanmall, Senior Research Analyst, Technology Evaluation & Medical Policy, Independence Blue Cross
Oct 2515:50
Conference pass

Employing Hospital Informatics for Antimicrobial Stewardship

Antimicrobial Stewardship
  • Identifying opportunities through baseline data for implementing interventions
  • Benefits and barriers to integrating external third party software and CPOEs
  • Prospectively identifying patients for targeted interventions – prospective audit with feedback and using alerts to intervene in real time
Benjamin Hammer, Co-leader of the Antimicrobial Stewardship Program, Children's National Health System
Rana Hamdy, Director, Antimicrobial Stewardship Program, Children's National Health System
Oct 2515:50
Conference pass

Vaccines in the global fight against AMR: Targeting the virulence or infection?

Innovation Showcase
  • Vaccines that can harm highlight the importance of virulence factors; what do we learn from staphylococcus aureus vaccines
  • Vaccines targeting virulence factors
  • IBT-V02 the first MRSA vaccine exclusively targeting virulence and the first vaccine supported by CARB-X
Javad Aman, Chief Executive Officer, Integrated Biotherapeutics
Oct 2516:10
Conference pass

Incentivizing antimicrobial development with novel HTA methodology and delinked payment - the UK journey so far

Antibiotic R&D
  • UK approach to adjusting HTA methodology to more fully assess the value of new antimicrobials
  • How might a novel HTA approach fit in with delinked payment schemes to incentivize new antimicrobial development in AMR arena
  • How might one deliver a novel HTA/delinked payment scheme in real world
Colm Leonard, Consultant Clinical Advisor, NICE
Oct 2516:10
Conference pass

Advanced informatics to improve microbiology lab performance and integrate clinical workflows

Diagnostics
  • Integrating laboratory systems and data with important clinical stakeholders
  • Provide actionable insights to help drive standardization and process improvement
  • Improve communication and information flow beyond the laboratory to enhance stewardship and clinical practice
Oct 2516:10
Conference pass

Panel - Hospital Antibiotic Stewardship programs – Challenges in infrastructure, education and data collection

Antimicrobial Stewardship
  • What is working in hospital ASPs today?
  • How do different funding structures impact stewardship efforts and what needs to change to continue to ASPs
  • Recommendations to advance both in-patient and out-patient stewardship programs
  • What technological advancements do hospitals need in order to monitor and reduce use of antibiotics in both in-patient and out-patient settings
Oct 2516:10
Conference pass

Simply using AI for discovering innovative actives against microbes and their biofilms

Innovation Showcase
  • Water Extracts of Complex Mixes of Edible Plants (WECMEPs) and AI for efficient elaboration of safe antimicrobials.
  • Current WECMEPs fighting MDR and XDR bacteria of highest concern to WHO and food safety.
  • Sustainable, personalized and rapid routes to manage acute, chronic and silent infections with WECMEPs, including for emergency responses to emerging microbes and bioterrorism.
Oct 2517:15
Conference pass

Keynote Address: Updates to Iclaprim clinical development program

Keynotes
  • Nearing commercialization: Updated data from two phase 3 clinical trials
  • New data from non-clinical trials including in-vitro testing, global surveillance, animal testing, different indications and pathogens
  • Navigating the regulatory approval process: filing NDA and NAH to the FDA and EMA respectively
  • What’s next? Looking to future studies to address high unmet medical needs
Oct 2517:35
Conference pass

Keynote CEO Panel: How to do business in a challenging environment - Current landscape for biotechs looking to commercialize or commercializing antimicrobials

Keynotes
  • How do you turn the current antibiotic development and commercialization model into one that is attractive to big pharma
  • Partnering and business development opportunities for smaller antibiotic biotechs – overcoming low stock prices
  • How can developing companies survive in this space and get continuous investments? Is the emergence of smaller companies the way to commercial viability and efficient distribution of resources
  • What is the investment landscape going to look like for up and coming companies
  • How to launch a product and demonstrate commercial success

Create your personal agenda –check the favourite icon

Oct 2608:55
Conference pass

Keynote address: A Crucial Time for Global Coordination – Harmonizing Action Against the Threats of Antimicrobial Resistance (AMR)

Keynotes
  • Working through the G7, G20, United Nations, and the Trans-Atlantic Task Force on Antimicrobial Resistance [TATFAR] to spur action to combat AMR
  • Partnerships for developing comparable stewardship programs to preserve the efficacy of the existing antimicrobial drugs
  • Strategies for improving the pipeline of new antimicrobial drugs, vaccines, and diagnostics through enhanced global collaboration
Oct 2609:20
Conference pass

Keynote address: Antimicrobial Therapy for Life-Threatening Infections: Speed is Life – the devastation of a delayed diagnosis

Keynotes
  • We think we know, but do we? What really are the true costs of sepsis? – Mary’s Story, a 360 degree view
  • Earlier targeted antibiotic therapy with T2MR technology: It can be done
  • Utilizing same-day sepsis pathogen ID for faster therapy, enhanced stewardship, improved outcomes in practice
Oct 2609:45
Conference pass

Keynote Address: Can non-traditional be our next line of defense? Challenges in non-traditional development, stewardship and diagnostic approaches

Keynotes
  • What are the most promising non-traditional therapeutics in the pipeline and are these commercially viable
  • Outlining an action plan for further development, partnered diagnostic development, and stewardship implications
  • Understanding clinical trial regulation and approval pathways for non-traditional in the U.S, Europe and beyond
  • How to get regulators, industry and payers more involved in new and non-traditional therapeutics
Jeff Stein, President and Chief Executive Officer, Cidara Therapeutics
Scott Stibitz, Center for Biologics Evaluation and Research (CBER), FDA
Paul Garofolo, Chief Executive Officer, Locus Biosciences
Steven Gilman, Chief Executive Officer, Contrafect Corporation
Oct 2611:10
Conference pass

Guidelines for successful clinical trials to tackle Hospital Acquired Pneumonia

Antibiotic R&D
  • Multi stakeholders working in industry, patients, public-private partnership collaboration
  • Risk prediction models for preventative hospital acquired pneumonia
  • Recommendations for biotechs looking to gain approvals for their drug through challenging clinical trials.
Pamela Tenaerts, Executive Director, Clinical Trials Transformation Initiative
Oct 2611:10
Conference pass

Update on FDA guidance for the coordinated development of antimicrobial drugs and antimicrobial susceptibility test devices

Diagnostics
  • Importance of coordinated development for both drug and device manufacturers
  • What has happened in the past year after the guideline implementation for AST
  • How are providers taking advantage of new developments to decrease time to approval and market
Oct 2611:10
Conference pass

Putting a One Health Approach to AMR into Action at Merck

Antimicrobial Stewardship
  • What does One Health mean and why is it important to AMR?
  • What are opportunities for One Health collaboration between human and animal health?
  • Are there any best practices for a One Health approach?
Oct 2611:10
Conference pass

Immunobiotics: Cloudbreak Antibody Drug Conjugates (ADC) as countermeasures against MDR bacterial infections

Innovation Showcase
  • ADCs tightly bind to conserved targets on the surface of Gram negative bacteria, demonstrating broader spectrum than monoclonal antibodies.
  • ADCs kill by direct bactericidal action and recruitment of specific innate immune system components, minimizing resistance potential.
  • ADCs possess extended half-lives to support once-weekly/bi-weekly dosing, making them suitable as both immunoprophylactic and immunoitherapeutic agents
Leslie Tari, Vice President, Discovery, Cidara Therapeutics
Oct 2611:30
Conference pass

Outer membrane protein targeting antibiotics (OMPTAs): A novel class with potent activity against Gram-negative organisms to combat resistance

Antibiotic R&D
  • Presenting an overview on the development of the OMPTA antibiotics
  • Particularly describing the development of murepavadin, a pathogen specific anti-pseudomonal antibiotic which has entered Phase 3
  • Describing the in vitro and in vivo activity of the new series of OMPTAs displaying potent coverage the gram-negative pathogens designated as critical by the WHO
Glenn Dale, Head of Early Development, Antimicrobials, Polyphor Ltd
Oct 2611:30
Conference pass

Ensuring availability of approved susceptibility tests

Diagnostics
  • Working with all stakeholders in susceptibility testing development, pharmaceutical companies, device manufacturer, clinical microbiology lab and physicians
  • Historical delays and potential solutions to streamline testing approvals and availability
  • Issues of research use only (RUO) testing devises
Oct 2611:30
Conference pass

Reforming payment to enhance stewardship and public health value

Antimicrobial Stewardship
  • Understanding how payer reimbursement models impact stewardship
  • Designing incentive and payment models that support stewardship
  • Adapting a long term economic outlook - new mindset and economic model for biotech and industry
Oct 2611:30
Conference pass

Utilizing bacteriophages to prevent infections

Innovation Showcase
    Traditionally companies and institutes have tried to develop bacteriophages as therapiesCommercial realties of therapies vs. preventatives
  • Phagelux Solutions: sustained release sprays and patches
Oct 2611:50
Conference pass

Antibiotic development for CABP, trials, hurdles and economics

Antibiotic R&D
  • Omadacycline development - trial design and execution
  • Enrollment challenges - costs, guidelines and quality metrics
  • Innovative trial designs and economics
Oct 2611:50
Conference pass

Diagnostics

Diagnostics
If you’re interested in sponsoring this session contact Fred Sansiveri at fred.sansiveri@terrapinn.com or +1 646 619 1838
Oct 2611:50
Conference pass

Engaging industry on stewardship best practices based on the first Antimicrobial Resistance Benchmark

Antimicrobial Stewardship
  • What are the antibiotic development opportunities for industry in low and middle income countries where the highest rates of resistance occur
  • Employing “access thinking” to product development and strategies for companies to monitor stewardship of their drugs on the market
  • Implementing best practices and identifying progress gaps based within the pharmaceutical industry
Gabrielle Breugelmans, Director of Research, Access to Medicine Foundation
Oct 2611:50
Conference pass

Potentiating host defenses against resistant P. aeruginosa in ventilator-associated pneumonia

Innovation Showcase
  • Will inhibition of a virulence factor be moreeffective in therapeutic or prophylactic applications?
  • Dimers of the inhibitor scaffold are extremelypotent, consistent with inhibiting the polymeric type III secretion needle
  • Monomers of the inhibitor scaffold are moredrug-like and are potent enough to display efficacy in a murine acute pneumoniainfection model
  • What are the risks for resistance development
Donald Moir, Chief Scientific Officer, Microbiotix Inc
Oct 2612:10
Conference pass

Clostridium difficile recurrent infections – a new approach to tackle this significant healthcare burden

Antibiotic R&D
  • Need for new C. difficile therapies and the importance of the microbiome to disease progression
  • Impact on recurrent infections by ridinilazole, a novel C. difficile targeting antibacterial, seen in Phase 2 clinical trials and its lack of impact on the gut microbiome
  • Present Summit’s innovative plans for the Phase 3 clinical trials due to start Q1 2019
Richard Vickers, SVP and CSO, Anti-Infectives, Summit Therapeutics
Oct 2612:10
Conference pass

Topic to be confirmed

Diagnostics
Reserved for Gold Sponsor If you’re interested in moderating a roundtable contact Fred Sansiveri at fred.sansiveri@ terrapinn.com or +1 646 619 1838
Oct 2612:10
Conference pass

Antimicrobial Stewardship

Antimicrobial Stewardship
Reserved for Gold Sponsor If you’re interested in moderating a roundtable contact Fred Sansiveri at fred.sansiveri@ terrapinn.com or +1 646 619 1838
Oct 2612:10
Conference pass

Innovation Showcase

Innovation Showcase
If your company is looking for funding or partnering opportunities, you should sponsor this session. Get in touch NOW with Fred Sansiveri at fred.sansiveri@terrapinn.com or +1 646 619 1838 to get more information.
Oct 2614:00
Conference pass

Roundtable 1: Vaccines vs. AMR – Outlining the important role vaccines play in combatting AMR and exploring the potential synergies between vaccines and antimicrobial drugs/ monoclonal antibodies to p

Keynotes
Timothy Cooke, Chief Executive Officer, NovaDigm Therapeutics
Oct 2614:00
Conference pass

Roundtable 10: Engaging Policymakers- Successful strategies to focus policymaker attention on AMR and build political will for advancing incentives, stewardship and additional policies and investments

Keynotes
Amanda Jezek, Senior VP, Public Policy and Government Relations, Infectious Diseases Society of America
Oct 2614:00
Conference pass

Roundtable 2: Non-traditional Approaches – Understanding the preclinical and clinical challenges associated with the discovery and development of non-traditional therapies

Keynotes
Wes Kim, Senior Officer, The Pew Charitable Trusts
Oct 2614:00
Conference pass

Roundtable 3: Hostcentricity – a discussion on the undeniable superorganisms of human and animal health, and their contribution to holistic and sustainable antimicrobial stewardship

Keynotes
Brian Michael Aldridge, Clinical Professor, Department of Veterinary Clinical Medicine, University of Illinois College of Veterinary Medicine
Oct 2614:00
Conference pass

Roundtable 4: Essential Diagnostics – Understanding the implications of WHO’s first ever Essentials Diagnostic List and why quality diagnostics are the linchpin to breaking the AMR Pandemic

Keynotes
Anthony Emeribe, Professor, University of Calibar, Nigeria and Member, WHO Strategic Advisory Group of Experts on In-Vitro Diagnostics (SAGE-IVD)
Oct 2614:00
Conference pass

Roundtable 5: MASTERMIND Diagnostics – Bringing microbial diagnostics to the clinic through a new clinical-trial design that brings together multiple stakeholders and maximizes trial efficiency by usi

Keynotes
Sarah Doernberg, Associate Professor, University of California, San Francisco
Oct 2614:00
Conference pass

Roundtable 6: Drug Reimbursement - Discussing the factors for and against proposed models - incentive-driven, pricing, and other business-based initiatives. Reviewing the variety of problems and solut

Keynotes
Eugean Jiwanmall, Senior Research Analyst, Technology Evaluation & Medical Policy, Independence Blue Cross
Oct 2614:00
Conference pass

Roundtable 7: Innovation incentives: fostering synergies among European states to pilot and implement pull incentives

Keynotes
Oct 2614:00
Conference pass

Roundtable 8: Industry Collaboration – Translating commitments across all fronts into meaningful impact in the fight against AMR

Keynotes
Oct 2614:00
Conference pass

Roundtable 9: Composite endpoints – the way to FDA approval for non-traditional antibiotics requires new thinking around endpoints in clinical trials. Are composite endpoints a way forward?

Keynotes
Marc Gitzinger, Chief Executive Officer And Co-Founder, Bioversys
Oct 2614:40
Conference pass

Sponsored Session

Innovation Showcase
If you’re a biotech developing a non-traditional antibiotic and you’re looking for funding or partnership opportunities, contact Fred Sansiveri at fred.sansiveri@terrapinn.com or +1 646 619 1838
Oct 2615:10
Conference pass

Forging innovation: leveraging credible funding and partnerships for novel class antibiotic pipeline expansion

Antibiotic R&D
  • Beyond grant funding: taking advantage of CARB-X due diligence and scientific approach to advance Forge’s metalloenzymes
  • How can strategic early stage partnerships for lead optimization and susceptibility testing gain the interest of investors?
  • Expanding pipeline to include multiple new novel class antibiotics
Oct 2615:10
Conference pass

FebriDx: A rapid Point of Care (POC) Test for the Simultaneous Detection of MxA and CRP to support outpatient antibiotic stewardship

Diagnostics
  • Identifying viral and bacterial infections through a combination of MxA and CRP biomarkers
  • Review of prospective, multi-center clinical trial and outcome study data
  • Supporting outpatient antibiotic stewardship through cost effective FebriDx testing
Oct 2615:10
Conference pass

Educating industry and policy makers: insights from global surveillance of resistance

Antimicrobial Stewardship
  • How to educate regulators, and practitioners based on human behavior studies and global surveillance of resistance
  • The need to further develop surveillance practices and infrastructure to continue to inform all stakeholders and guide stewardship practices
  • Recommendations to incorporate epidemiology, practitioner behavior and stewardship into drug development and commercial design
Oct 2615:30
Conference pass

The Priority Antimicrobial Value and Entry (PAVE) Award proposal

Antibiotic R&D
  • Market entry reward with shift to value-based reimbursement for antimicrobials
  • Incentivizing the shift from volume to value
  • Leverages public and private funds to accomplish delinkage while supporting stewardship and availability
Gregory Daniel, Deputy Director, Duke University
Oct 2615:30
Conference pass

RADICAL: Rapid Diagnostics in Categorizing Acute Lung Infections

Diagnostics
  • The inability to discriminate bacterial, viral, and non-infectious illness continues to drive inappropriate antibiotic use
  • The host’s molecular response to disease is able to discriminate between bacterial, viral, and non-infectious illness
  • Host response signatures measured on technologically advanced platforms has created a new diagnostic paradigm
Ephraim Tsalik, Associate Professor of Medicine Division of Infectious Diseases, Duke University Medical Center
Oct 2615:30
Conference pass

The United Arab Emirates’ National AMR Surveillance program and how the private sector is contributing to resistance data collection

Antimicrobial Stewardship
  • Current ID landscape in Dubai & United Arab Emirates overall
  • Overcoming challenges in implementing critical ASPs in the private sector and how to replicate successes
  • Unpacking how the private sector in United Arab Emirates has contributed to national surveillance resistance
Dirar Abdullah, Head, Adult Critical Care Services, Chair, Antibiotic Committee and Antibiotic Stewardship Program, Prime Hospital- Dubai
last published: 21/Sep/18 19:05 GMT

SIGN UP FOR EVENT UPDATES